SEC EDGARJUN 22 min read$GILD

O'Day Daniel Patrick sold $405K of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 3,062 shares of GILEAD SCIENCES, INC. (GILD) at $132.22 ($0.40M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · O'Day Daniel Patrick

Published Jun 2, 2026, 10:04 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 2, 2026, 10:06 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$GILD

Neutral

medium confidence

Mentioned

$GILD

Relevance

6/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$GILDNeutralLow

Why it matters

The disclosure provides incremental sentiment information but does not introduce new company fundamentals (no earnings, trial, guidance, deal, or regulatory event).

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 pre-arrangement reduces the likelihood of a durable negative reprice.

What to watch

Insider sales can cluster around scheduled plans; without additional filings (e.g., buys, option exercises, or changes in plan size), signal-to-noise is low.

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-02 after the 2026-06-01 sale under a 10b5-1 plan.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO/Chairman under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GILDNeutralMedium confidence

Context

Gilead CEO/Chairman O’Day sold $404.8K of GILD shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief unless accompanied by other news.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 pre-arrangement, providing disclosure but not a new operational or financial catalyst.

Market effects

Sector

Minimal; this is company-specific insider disclosure without sector-wide catalyst.

Regional

Minimal; US-listed large-cap disclosure unlikely to drive broader regional flows.

Global

Minimal; no international transaction or regulatory action described.

Counterpoint

What could challenge this read

Because the sale is pre-arranged, it may be more about liquidity/tax planning than bearish expectations; the market may overreact.

Key entities

issuer
Gilead Sciences, Inc.
Subject of the insider transaction disclosure (Form 4) involving CEO/Chairman O’Day.
insider
O’Day Daniel Patrick
CEO/Chairman who sold 3,062 shares at $132.2151 on 2026-06-01 under a 10b5-1 plan.

Read at source ← All news

SEP 5

$GILDHighAI 8/10

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Gilead Sciences (GILD) received three FDA approvals in four months, boosting its stock 21% YTD. Recent approvals include Bixlenvo for HIV and Trodelvy for breast cancer. The company expects more approvals, including anito-cel for multiple myeloma by year-end. Gilead's Q2 revenue was $7.6B, up 8% YoY, with strong HIV drug sales. The company raised its dividend to $0.82, yielding 2.15%.

yahoo.com3 min

SEP 3

$GILDHighAI 8/10

Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?

Gilead Sciences (GILD) shares rose 13.6% since its last earnings report. Q2 2026 saw a narrower adjusted loss of $6.75 per share and revenue growth of 10% to $7.80 billion, driven by HIV portfolio and Trodelvy. GILD raised full-year HIV sales growth guidance to 9-10%.

finance.yahoo.com3 min

SEP 2

$MRKLowAI 8/10

Once-Weekly Oral Combination HIV Pill Shows Promise As Alternative to Daily Treatment

Merck and Gilead Sciences are developing a weekly oral HIV treatment combining islatravir and lenacapavir, both FDA-approved separately. The combination aims to offer an alternative to daily HIV medication.

healthandme.com1 min

SEP 2

$GILDHighAI 9/10

Tablet Regimen for Virologically Suppressed Adults Living with HIV

The FDA approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV treatment for virologically suppressed adults. The drug combines bictegravir and lenacapavir, simplifying therapy and reducing pill burden. Clinical trials showed non-inferior viral suppression rates and improved health metrics. Bixlenvo is designed for patients with complex treatment histories or resistance challenges.

geneonline.com2 min

AUG 31

$GILDHighAI 9/10

A new once-daily pill to treat HIV just got the FDA’s green light

The FDA approved Gilead Sciences' once-daily HIV pill, Bixlenvo, for adults with suppressed HIV who cannot use current single-pill treatments. It combines bictegravir and lenacapavir, with a list price of $4,595 per month. Gilead aims to provide more treatment options, especially for older patients with complex regimens. According to the company, this group represents about 5% of HIV patients in the U.S.

advocate.com2 min